Impact of sodium-glucose cotransporter-2 inhibitors on aging biomarkers and plasma ceramide levels in type 2 diabetes: beyond glycemic control.

Youssef M Shalaby, Mohammed Moutaz Nakhal, Bachar Afandi, Bashar Al-Zohily, Lina Majed, Kukkala Kiran Kumar, Bright Starling Emerald, Bassem Sadek, Amal Akour, Nadia Akawi

Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, UAE.Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, UAE. · pubmed

Paper

Abstract

Aging is a complex biological process marked by the decline of physiological functions and heightened susceptibility to chronic illnesses, notably cardiometabolic disorders. Ceramides (Cer) are lipid derivatives linked to aging and metabolic diseases. Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i), widely used in managing type 2 diabetes, have an unclear impact on aging biomarkers and Cer profiles.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the effects of SGLT2 inhibitors on aging biomarkers and ceramide levels in type 2 diabetes. This research is relevant as it explores potential mechanisms that could influence aging processes and metabolic health, rather than merely addressing symptoms of age-related diseases.

Author of this paper? Send a correction.